Jeffrey A. Meckler - 27 Jul 2025 Form 4 Insider Report for Indaptus Therapeutics, Inc. (INDP)

Role
Chief Executive Officer, Director
Signature
/s/ Jeffrey Meckler
Issuer symbol
INDP
Transactions as of
27 Jul 2025
Net transactions value
+$151,137
Form type
4
Filing time
29 Jul 2025, 16:15:27 UTC
Previous filing
16 May 2025
Next filing
29 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Meckler Jeffrey A Chief Executive Officer, Director C/O INDAPTUS THERAPEUTICS, INC, 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK /s/ Jeffrey Meckler 29 Jul 2025 0001506916

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INDP Common Stock Award $50,379 +6,068 +84% $8.30 13,312 27 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INDP Common Stock Warrants Award $100,758 +12,136 +267% $8.30 16,688 27 Jul 2025 Common Stock 12,136 $8.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person acquired 6,068 shares of common stock and 12,136 warrants to purchase common stock from the Issuer following the mandatory conversion of a convertible note that the Reporting Person acquired from the Issuer in a private placement in June 2025 at a conversion price of $8.3024, which is equal to 80% of the average closing price of the Issuer's shares of common stock on the Nasdaq Capital Market for the five trading days immediately preceding and including the conversion date of July 27, 2025.

Remarks:

On June 26, 2025, the Company implemented a 1-for-28 reverse stock split (the "Reverse Stock Split") of the Company's common stock. All amounts have been adjusted to give effect to the Reverse Stock Split.